Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 5/21/21 → 1/29/25 |
Funding
- Merck Sharp & Dohme Corporation: $80,022.00
MK5475-007: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study To Evaluate The Efficacy And Safety Of MK-5475 In Adults With Pulmonary Arterial Hypertension
- Booth, David (PI)